title: Advances in management of adjuvant chemotherapy in rectal cancer: Consequences for clinical practice.
abstract: More than half the patients with rectal cancer present with locally advanced rectal disease at diagnosis with a high risk of recurrence. Preoperative chemoradiotherapy and standardized radical surgery with total mesorectal excision have been established as the 'gold standard' for treating these patients. Pathological staging using the ypTNM classification system to decide on adjuvant chemotherapy (ACT) is widely used in clinical practice, but the delivery of ACT is still controversial, as many discrepancies persist in the conclusions of different trials, due to heterogeneity of the inclusion criteria between studies, lack of statistical power, and variations in preoperative and adjuvant regimens. In 2014, a meta-analysis of four randomized phase-III trials (EORTC 22921, I-CNR-RT, PROCTOR-SCRIPT, CHRONICLE) failed to demonstrate any statistical efficacy of fluorouracil (5FU)-based ACT. Three recent randomized trials aimed to compare 5FU with 5FU plus oxaliplatin-based chemotherapy. Two of them (ADORE, CAO/ARO/AIO-04) appeared to find a disease-free survival benefit for patients treated with the combination therapy. Thus, while awaiting new data, it can be said that, as of 2015, patients with yp stage I tumors or histological complete response derived no benefit from adjuvant therapy. On the other hand, the FOLFOX chemotherapy regimen should be proposed for yp stage III patients, and may be considered for yp stage II tumors in fit patients with high-risk factors. Nevertheless, well-designed and sufficiently powered clinical trials dedicated to adjuvant treatments for rectal cancer remain justified in future to achieve a high level of proof in keeping with evidence-based medical standards.
authors.affiliation: Université Paris Descartes, Department of Hepatogastroenterology and GI Oncology, hôpital européen Georges-Pompidou, 75015 Paris, France.
authors.forename: Jeanne
authors.initials: J
authors.lastname: Netter
authors.affiliation: Université Paris Descartes, Department of Hepatogastroenterology and GI Oncology, hôpital européen Georges-Pompidou, 75015 Paris, France.
authors.forename: Richard
authors.initials: R
authors.lastname: Douard
authors.affiliation: Université Paris Descartes, Department of Hepatogastroenterology and GI Oncology, hôpital européen Georges-Pompidou, 75015 Paris, France.
authors.forename: Catherine
authors.initials: C
authors.lastname: Durdux
authors.affiliation: Université Paris Descartes, Department of Hepatogastroenterology and GI Oncology, hôpital européen Georges-Pompidou, 75015 Paris, France.
authors.forename: Bruno
authors.initials: B
authors.lastname: Landi
authors.affiliation: Université Paris Descartes, Department of Hepatogastroenterology and GI Oncology, hôpital européen Georges-Pompidou, 75015 Paris, France.
authors.forename: Anne
authors.initials: A
authors.lastname: Berger
authors.affiliation: Université Paris Descartes, Department of Hepatogastroenterology and GI Oncology, hôpital européen Georges-Pompidou, 75015 Paris, France. Electronic address: julien.taieb@egp.aphp.fr.
authors.forename: Julien
authors.initials: J
authors.lastname: Taieb
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D059186:Chemoradiotherapy, Adjuvant; D017024:Chemotherapy, Adjuvant; D006801:Humans; D015201:Meta-Analysis as Topic; D016032:Randomized Controlled Trials as Topic; D012004:Rectal Neoplasms / Q000473:pathology / Q000628:therapy*